| 61.075 2.115 (3.59%) | 10-15 12:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 76.06 | 1-year : | 88.83 |
| Resists | First : | 65.12 | Second : | 76.06 |
| Pivot price | 57.78 |
|||
| Supports | First : | 33.31 | Second : | 13.64 |
| MAs | MA(5) : | 61.35 |
MA(20) : | 48.51 |
| MA(100) : | 21.82 |
MA(250) : | 15.92 |
|
| MACD | MACD : | 10.4  |
Signal : | 10.4 |
| %K %D | K(14,3) : | 82.5 |
D(3) : | 88.5 |
| RSI | RSI(14): 73.8 |
|||
| 52-week | High : | 65.12 | Low : | 5.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QURE ] has closed below upper band by 29.2%. Bollinger Bands are 10.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.59 - 61.9 | 61.9 - 62.16 |
| Low: | 57.88 - 58.2 | 58.2 - 58.46 |
| Close: | 58.49 - 58.99 | 58.99 - 59.4 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Mon, 13 Oct 2025
uniQure N.V. $QURE Shares Purchased by Aberdeen Group plc - MarketBeat
Sat, 11 Oct 2025
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Fri, 10 Oct 2025
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Wed, 08 Oct 2025
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
Mon, 06 Oct 2025
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
Tue, 30 Sep 2025
uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 11,030 (K) |
| Shares Short P.Month | 9,060 (K) |
| EPS | -3.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | -790.8 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -427.5 % |
| Qtrly Rev. Growth | -52.8 % |
| Gross Profit (p.s.) | -1.98 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -2.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -173 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -15.54 |
| PEG Ratio | 0 |
| Price to Book value | -865.72 |
| Price to Sales | 260.31 |
| Price to Cash Flow | -21.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|